Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the safety and effectiveness of Interferon
gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by
inhalation (breathed into the lungs) three times a week for 12 weeks.
The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is
the condition being examined in this study.